
Metsera, Inc. (NASDAQ:MTSR) on Tuesday released topline data from VESPER-1 and data from a planned interim analysis for tolerability of VESPER-3 – two Phase 2b trials of MET-097i with potential for monthly dosing.
In VESPER-1, MET-097i demonstrated a mean placebo-subtracted weight loss of up to 14.1% after 28 weekly doses.